FROM THE EDITOR
The five $10 billion-plus pharma acquisitions that closed in Q2 2026 are now in integration. Merck is integrating Terns. Biogen is integrating Apellis. Lilly is integrating Centessa. Each of those acquisitions absorbed companies with multiple programs, multiple CDMO relationships, multiple clinical teams, and multiple commercial commitments. Not everything acquired was intended to be kept. Not everything kept will be prioritized at the same level.
This is the dynamic that creates the H2 2026 opportunity for PE-backed specialty pharma platforms and mid-market acquirers. The programs that go from ‘actively advancing’ to ‘evaluating strategic options’ in the acquirer’s next pipeline update are the assets that are available — not yet in a banker-run process, not yet repriced by a formal sale, and not yet competing against every other buyer who reads the same announcement at the same time. The bilateral conversation that happens three weeks before the process is formally launched is where PE pharma platforms build competitive advantage in this market.
Seventy-one percent of private equity firms are actively evaluating carve-out transactions in 2026. Fifty-seven percent of corporations are open to or actively exploring divestitures. PwC forecasts additional PE-led carve-outs from large pharma integrations in H2. The carve-out has moved from opportunistic to central as a deal sourcing strategy. What makes pharma carve-outs different from generic corporate carve-outs is the legal architecture — and that is where the CLO’s preparation determines whether the deal gets done on the right terms.
The carve-out opportunity is real. The legal complexity of executing it is specific.
— John LaRocca
Founding Editor | LaRocca Advisory Group
The Carve-Out Is Now Central: Acquiring Programs from Major Pharma Integrations — the CLO’s Playbook
Why the Carve-Out Is Different in Pharma
A non-pharma corporate carve-out separates a business unit from its parent — a division, a brand portfolio, a commercial franchise. The assets being carved out are primarily commercial: customer relationships, revenue streams, contracts, and employees. The legal work is primarily about separation — creating standalone versions of shared services, transitioning contracts, and ensuring the carved-out business can operate independently.
A pharma carve-out separates a development program from its parent. The assets being carved out are primarily regulatory and scientific: IND applications, clinical trial data, FDA meeting correspondence, CDMO relationships, manufacturing process documentation, and clinical team expertise. The legal work is not primarily about commercial separation. It is about regulatory transfer, data ownership, IP chain of title, and the manufacturing supply bridge that keeps the program operational through the transition.
The CLO who approaches a pharma carve-out with a generic M&A carve-out framework will miss the things that matter most. This article covers five legal domains that are specific to pharma carve-outs and absent from standard carve-out legal work.
The Carve-Out Pipeline: Where to Look in H2 2026
The specific programs to watch are not yet in public carve-out announcements. They are visible in the acquirers’ pipeline prioritization language.
Signals to Monitor
• A program moves from ‘Phase X advancing’ to ‘Phase X — under review’ in the acquirer’s quarterly pipeline update
• A therapeutic area is described as ‘not a strategic priority’ or ‘outside the core focus’ following the acquisition
• The acquired company’s leadership in a specific area is described as ‘evaluating their next role’ in press coverage
• A clinical trial for an acquired program posts a status change to ‘suspended’ or ‘terminated’ on ClinicalTrials.gov
• Business development contacts at the acquiring company begin responding to inquiries about specific programs that were previously described as internally prioritized
These signals typically appear 60-180 days after a transaction closes. The Biogen/Apellis integration closed May 14. The Merck/Terns integration closed May 5. The Lilly/Centessa integration closed June 24. The 60-180 day window for visible deprioritization signals runs from July through December 2026. The PE platform whose business development team is monitoring these signals systematically has a structural sourcing advantage over the acquirer who responds to the banker’s call when the formal process launches.
The Legal Architecture of a Pharma Carve-Out
Domain 1: Regulatory Asset Transfer
An IND cannot simply be assigned. The holder of an IND is the sponsor — the party responsible to FDA for the conduct of the clinical investigation. Transferring sponsorship requires written notification to FDA, FDA’s acknowledgment, and a period during which both the transferor and transferee are coordinating their respective FDA relationships. The acquirer must be ready to assume the sponsor responsibilities on Day 1 of the transfer: IND amendments, safety reporting, site correspondence, and protocol submissions.
The regulatory transfer due diligence must cover: the complete IND file and all amendments; every Type A, Type B, and Type C meeting summary; every clinical hold and company response; every DSMB/DMC report; and every study protocol submission and FDA response. These documents are the regulatory relationship with FDA. The acquirer who does not have them cannot manage that relationship.
NDA and BLA transfers, where the acquired program has reached regulatory submission, are more complex: FDA requires the prior holder to formally withdraw or relinquish the application and the new holder to file a new application or an amendment reflecting the change in applicant. The transition period — during which the product is technically marketed but the regulatory relationship is in transition — requires detailed coordination with FDA and is a CLO workstream that begins at signing, not at closing.
Domain 2: IP Chain of Title
The IP in a pharma carve-out has almost certainly been assigned, licensed, and amended multiple times before the carve-out. The compound may have originated at a university or research institution, been exclusively licensed to the target company, been sublicensed to a CDMO for manufacturing, and been the subject of a co-development agreement with a prior partner. Each layer of that chain must be traced and confirmed before the carve-out closes.
The specific IP chain of title questions in a pharma carve-out:
• Does the carve-out agreement transfer ownership of the compound IP, or just a license to use it? Ownership and exclusive license are not the same thing in a carve-out — the form of the transfer determines what the acquirer can do with the asset, including sublicensing, partnering, and enforcement.
• Are there upstream licenses from academic institutions, research collaborations, or prior development partners that encumber the transferred IP? Every upstream license survives the carve-out unless it is explicitly terminated or assigned. The acquirer inherits the obligations.
• Are there patent prosecution obligations — maintenance fees, continuation decisions, foreign filing deadlines — that are currently managed by the parent and must be transferred to the acquirer’s IP management systems with no gap?
• Are there co-inventors at universities or research institutions whose assignments were obtained at the time of the original invention disclosure, and have those assignments been maintained in the patent prosecution record?
• Does the parent retain any IP license-back rights post-carve-out — rights to use the transferred technology in the parent’s own programs? If so, those rights must be defined with precision in the carve-out agreement, because they determine the exclusivity of what the acquirer is buying.
Domain 3: CDMO and Supply Agreement Transfer
Every clinical-stage program has a CDMO providing drug substance and drug product for clinical supply. The CDMO agreement governs the relationship with the manufacturer who keeps the program operational. In a pharma carve-out, that CDMO agreement must be either assigned to the acquirer or a new agreement must be negotiated before closing.
Change-of-control provisions in CDMO agreements are a very common source of post-closing operational disruption in pharma carve-outs. A CDMO agreement that permits the CDMO to terminate upon a change of control of the customer gives the CDMO leverage to renegotiate the pricing terms at the worst possible moment — when the carve-out has just closed and the acquirer has no alternative manufacturing relationship ready. The CLO’s pre-signing diligence must include a review of every CDMO agreement for change-of-control provisions, and the carve-out agreement must include a condition or covenant requiring the CDMO’s consent to the assignment before closing.
Section 232 tariff exposure adds a layer that did not exist before April 2026. A carve-out program whose API is sourced from a non-exempt country may carry ongoing tariff exposure that the acquirer is assuming. The HTSUS classification of the API and key starting materials must be completed before the carve-out diligence is finished, and the cost of goods model must reflect the tariff exposure at each pricing tier.
Domain 4: Clinical Trial Transfer
Active clinical trials in a carved-out program must continue without interruption through the carve-out process. The transition from one sponsor to another, managed incorrectly, can constitute a protocol deviation at every active site. Sites must be notified of the sponsor change; IRB/Ethics Committee approvals must be updated; site contracts must be novated or reassigned; and the safety reporting obligations must be continuous from the moment the transfer begins.
The transition services agreement (discussed below) must include explicit provisions for the period between signing and closing during which the program continues to be run by the parent company on behalf of the eventual acquirer. The clinical trial data must be transferred to the acquirer’s data management systems with full audit trail integrity. Any gap in the audit trail is a GxP data integrity issue.
Domain 5: The Transition Services Agreement
The Transition Services Agreement (TSA) is the contract that governs how the parent company continues to provide services to the carved-out program after closing, until the acquirer has stood up its own capabilities. In a generic corporate carve-out, TSA services are typically back-office: IT, HR, finance, payroll. In a pharma carve-out, the TSA services also include clinical and regulatory: clinical trial management, pharmacovigilance, regulatory affairs, CDMO relationship management, and quality management.
The pharma TSA is vital and yet is the most commonly underbuilt document in a pharma carve-out. The specific risks: the TSA services are provided by the parent’s employees, who owe their primary employment obligation to the parent, not to the carved-out program; those employees will be transitioned, terminated, or reassigned on the parent’s timeline, not the acquirer’s; and the quality of the TSA services degrades as the parent’s integration proceeds and the employees who knew the carved-out program are absorbed into different roles. The CLO must negotiate TSA service levels (i.e., minimum staffing, minimum quality metrics, escalation procedures) and TSA duration terms that reflect the realistic time it takes to stand up independent clinical and regulatory operations.
THE BILATERAL SOURCING ADVANTAGE
The carve-out opportunity that produces the best acquisition economics is the one identified before the formal process is launched. A PE platform that approaches the acquiring company’s business development team, meaning not through a banker or through a public process, and expresses specific, knowledgeable interest in a specific deprioritized program before any formal sale decision has been made is the potential acquirer best positioned to negotiate bilateral terms. The complexity of separating a clinical-stage program from its parent tends to thin the field of potential buyers which is the entry pricing advantage the carve-out market provides. That advantage is largest before the process is formalized.
WORKSTREAM 1 IMMEDIATE
Build the Carve-Out Monitor and Start Running It
The carve-out monitor is a systematic tracking system for the integration announcements, pipeline updates, and business development communications from the five largest Q2 2026 acquirers: Biogen, Merck, Lilly, Sanofi (Blueprint Medicines close), and Vertex (Crinetics acquisition). The monitor tracks: quarterly pipeline updates for each acquirer, with changes in program status flagged; ClinicalTrials.gov status changes for programs associated with the acquired companies; press coverage and business development team communications referencing the acquired pipeline; and any conference presentations by the acquired companies’ scientific leadership post-close. The monitor runs on a biweekly cycle. Any signal that a program has moved from ‘actively advancing’ to ‘under review’ or ‘evaluating strategic options’ triggers a business development outreach to the acquirer’s relevant team within two weeks. Two weeks is the window between when a deprioritization decision is internal and when a formal sale process is launched.
BUSINESS IMPACT: The PE platform that identifies a carve-out opportunity before the banker is engaged negotiates bilaterally. The PE platform that responds to the banker’s call negotiates in an auction. These are different markets, at different prices, with different CLO workstreams.
WORKSTREAM 2 NEAR-TERM
Build the Pharma Carve-Out Diligence Protocol
The standard M&A diligence protocol does not cover the five pharma-specific domains identified in this article: regulatory asset transfer, IP chain of title in a layered licensing structure, CDMO change-of-control provisions, clinical trial transfer continuity, and TSA adequacy. Build the pharma carve-out diligence protocol as a standing document — a checklist of the 40-50 diligence items specific to a clinical-stage program carve-out — before the specific deal is identified. When the carve-out opportunity surfaces, the protocol is ready to deploy in days, not weeks. The protocol should be built with the same expertise structure as the speculative asset diligence protocol described in the August 2026 GC Playbook analysis: regulatory affairs counsel for the IND transfer assessment, CMC subject matter experts for the CDMO and manufacturing questions, clinical operations expertise for the trial transfer, and IP chain of title specialists for the licensing structure review.
BUSINESS IMPACT: A PE platform that deploys a complete pharma carve-out diligence protocol in three weeks signals to the seller that it knows what it is buying. A platform that spends six weeks discovering the legal architecture of the carve-out signals that it does not. Sellers reward speed and expertise with fewer conditions and better terms.
WORKSTREAM 3 STRATEGIC
Negotiate the TSA Before Closing, Not After
The TSA negotiation is the most consequential part of a pharma carve-out that most buyers treat as an afterthought. The parent company’s incentive in the TSA is to provide services for the shortest possible time at the minimum service level required to avoid breach. The buyer’s need is for clinical and regulatory continuity until it has built the independent capability to manage the program without the parent. Those incentives do not align, and the TSA is where the gap shows up. Negotiate the TSA as a primary document alongside the carve-out agreement, not as a schedule to be finalized after signing. Specific terms to insist on: named key personnel for each TSA service (not just ‘qualified personnel’); minimum quality metrics for clinical trial management and pharmacovigila
nce; a notification requirement if any named key person changes their role or employment status; and a right to step in and assume TSA services directly if the parent fails to meet service level requirements within a defined cure period. The TSA duration should reflect the realistic buildup timeline, which for clinical and regulatory operations is 12-18 months, not 6.
BUSINESS IMPACT: A TSA that expires before the acquirer has built its own clinical operations capability leaves the program without sponsor management at the worst possible time. That gap produces protocol deviations at active clinical sites, potential FDA findings, and recruiting pressure as the parent’s employees who were managing the program are no longer available.
“The carve-out opportunity in H2 2026 is real, and the PE platform that has built the carve-out monitor and the diligence protocol before the specific opportunity surfaces will close the bilateral deal that everyone else bids on in an auction.”


